Page 180 - Haematologica May 2022

Letters to the Editor
firm this observation. Last, the long-term impact of TAH on liver function could not be determined here.15 Despite these limitations, our results provide novel insights regarding the impact of ALL treatment on HL and the risk of TAH in overweight/obese patients, providing guidance for future study designs that integrate potentially hepato- toxic novel therapeutics, and supporting further investi- gation of underlying pharmacogenomic contributors to TAH.
Joanna S. Yi,1 Tiffany M. Chambers,1 Kelly D. Getz,2 Tamara P. Miller,3 Evanette Burrows,2 Marla H. Daves,1 Philip J. Lupo,1 Michael E. Scheurer,1 Richard Aplenc,2 Karen R. Rabin1 and Maria M. Gramatges1
1Baylor College of Medicine, Texas Children’s Cancer and Hematology Centers, Houston, TX; 2University of Pennsylvania Perelman School of Medicine, Children's Hospital of Philadelphia, Philadelphia, PA and 3Emory University School of Medicine, Children’s Healthcare of Atlanta, Atlanta, GA, USA
Correspondence:
JOANNA S. YI - Joanna.yi@bcm.edu doi:10.3324/haematol.2021.279805 Received: August 11, 2021.
Accepted: January 12, 2022. Pre-published: January 27, 2022. Disclosures: no conflicts of interest to disclose
Contributions: MMG, KRR, and RA conceptualized the study. KDG, TPM, EB, MHD, and RA abstracted the data. TMC and MES cleaned the data and performed all analyses with input from JSY, KDG, TPM, PJL, KRR, and MMG. JSY and MMG wrote the manuscript with significant editing from TMC, MES, and KRR.
Funding: the authors would like to thank the following funding sources: Alex’s Lemonade Stand Foundation (ALSF) Epidemiology Award (to RA), ALSF Young Investigator Award (to KDG), St. Baldrick’s Consortium Grant with generous support from the Micaela’s Army Foundation (to PJL, KRR, and MES), Cancer Prevention and Research Institute of Texas #RP160771 (to MES), National Institutes of Health (NIH) National Cancer Institute (5K12CA090433-17, Principal investigator: Dr. Susan Blaney, support for JSY and 1P20CA262733-01, Principal investigators: Lupo and Rabin), NIH National Heart, Lung, and Blood Institute Career Development Award 5K01HL143153 (to KDG), and NIH National Cancer Institute Career Development Award K07CA211956 (to TPM)..
Data-sharing statement: data from LEARN may be accessed by investigators who submit an application that is reviewed and approved by the study team.
References
1. Hunger SP, Mullighan CG. Acute lymphoblastic leukemia in chil- dren. N Engl J Med. 2015;373(16):1541-1552.
2. Hough R, Vora A. Crisis management in the treatment of childhood acute lymphoblastic leukemia: putting right what can go wrong (emergency complications of disease and treatment). Hematology Am Soc Hematol Educ Program. 2017;2017(1):251-258.
3. Schmiegelow K, Pulczynska M. Prognostic significance of hepatotox- icity during maintenance chemotherapy for childhood acute lym- phoblastic leukaemia. Br J Cancer. 1990;61(5):767-772.
4. Farrow AC, Buchanan GR, Zwiener RJ, et al. Serum aminotrans- ferase elevation during and following treatment of childhood acute lymphoblastic leukemia. J Clin Oncol. 1997;15(4):1560-1566.
5. Adam de Beaumais T, Dervieux T, Fakhoury M, et al. The impact of high-dose methotrexate on intracellular 6-mercaptopurine disposi- tion during interval therapy of childhood acute lymphoblastic leukemia. Cancer Chemother Pharmacol. 2010;66(4):653-658.
6. Segal I, Rassekh SR, Bond MC, et al. Abnormal liver transaminases and conjugated hyperbilirubinemia at presentation of acute lym- phoblastic leukemia. Pediatr Blood Cancer. 2010;55(3):434-439.
7. McAtee CL, Schneller N, Brackett J, et al. Treatment-related sinu- soidal obstruction syndrome in children with de novo acute lym- phoblastic leukemia during intensification. Cancer Chemother Pharmacol. 2017;80(6):1261-1264.
8. Ebbesen MS, Nygaard U, Rosthoj S, et al. Hepatotoxicity during maintenance therapy and prognosis in children with acute lym- phoblastic leukemia. J Pediatr Hematol Oncol. 2017;39(3):161-166.
9. Denton CC, Rawlins YA, Oberley MJ, et al. Predictors of hepatotox- icity and pancreatitis in children and adolescents with acute lym- phoblastic leukemia treated according to contemporary regimens. Pediatr Blood Cancer. 2018;65(3):e26891.
10. Hashmi SK, Navai SA, Chambers TM, et al. Incidence and predictors of treatment-related conjugated hyperbilirubinemia during early treatment phases for children with acute lymphoblastic leukemia. Pediatr Blood Cancer. 2019;67(2):e28063.
11. Goggins WB, Lo FF. Racial and ethnic disparities in survival of US children with acute lymphoblastic leukemia: evidence from the SEER database 1988-2008. Cancer Causes Control. 2012;23(5):737-743.
12. Faulk KE, Anderson-Mellies A, Cockburn M, et al. Assessment of enrollment characteristics for Children's Oncology Group (COG) upfront therapeutic clinical trials 2004-2015. PLoS One. 2020;15(4):e0230824.
13. Miller TP, Li Y, Getz KD, et al. Using electronic medical record data to report laboratory adverse events. Br J Haematol. 2017;177(2):283- 286.
14. Bhatia S, Sather HN, Heerema NA, et al. Racial and ethnic differences in survival of children with acute lymphoblastic leukemia. Blood. 2002;100(6):1957-1964.
15. Castellino S, Muir A, Shah A, et al. Hepato-biliary late effects in sur- vivors of childhood and adolescent cancer: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2010;54(5):663- 669.
1188
haematologica | 2022; 107(5)